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Abstract 
Prostate cancer is a common phenomenon among the male population in the world and often, it 
is a leading cause of death. From a pathohistological aspect, it is an adenocarcinoma which most 
often occurs in people over the age of 50. In this research is presented the occurrence of prostate 
cancer in the municipality of Prilep in terms of number and age of patients in the period from 
2014 to 2019. This research was conducted at the Center for Public Health in Prilep. The 
research is based on the period from 01.01.2014 to 31.12.2019, during which a total of 228 
patients were registered. According to the data received from the Center for Public Health - 
Prilep, it can be concluded that the most diagnosed patients are in the period from 01.01.2014 to 
31.12.2014. While according to age in the period from 2014 to 2019 the most common age group 
with prostate cancer are the patients between 65-74 years, then over 75 years, while the least 
diagnosed patients are aged 45-64 years. The purpose of this research is to determine the number 
of patients with prostate cancer in relation to the age of the patients, in order to give adequate 
and therapeutic care, which will aim to improve the treatment and prevention of prostate cancer. 
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Introduction 
The prostate is an exocrine gland that is part of the male reproductive system. It is made up of 
50-60 tubular alveolar glands with its own outflow tract, so that the secretion created by these 
glands becomes part of the ejaculate. Prostate cancer is one of the few pathological conditions 
that occur in the prostate. Prostate cancer is especially present in men over the age of 65, but the 
risk of developing this cancer increases beyond the age of 50. 
Pathogenetically, the occurrence of this cancer is on two bases: biological and genetic, where 
androgen hormones, the active metabolite of testosterone, ie dihydrotestosterone, are considered 
to play a major role, which is considered to be the cause of prostate cancer. Due to binding to 
androgen receptors in the prostate and stimulation of abnormal growth of prostate cells. This 
cancer rarely shows any symptoms, so some urologists believe that screening the male 
population over the age of 50 once a year can lead to early diagnosis and timely treatment of 
patients. 
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According to some epidemiological studies that have been done regarding prostate cancer, they 
have found that certain genetic changes and the occurrence of prostate cancer in a family 
increase the possibility of its occurrence in one of the heirs. According to these researches, in 5-
10% of the patients there is a positive family history, which with the presence of prostate cancer 
in a brother or father increases 2-3 times the possibility of its occurrence in other members of the 
family. The risk of prostate cancer increases in men who have a family history of breast or 
ovarian cancer, which in turn is associated with mutations in the BRCA1 and BRCA2 genes. 
Prostate cancer is rare in young people, but the risk increases with age, especially the risk 
increases enormously in people after the age of 50. This cancer is rare before the age of 45, while 
three-quarters of its occurrence occurs in men over the age of 65. 
Regional and national variations have shown that prostate cancer varies in certain ethnic 
communities. African Americans have the highest, while in Asia the incidence is the lowest. 
People of black descent not only have the highest incidence of the disease, but they also have a 
more aggressive and severe course of the disease. Differences between ethnic communities can 
be caused by differences in the gene alleles responsible for the enzymes involved in testosterone 
metabolism, as well as the risk of being influenced by the external environment and different 
lifestyles that are different for all ethnicities. 
There is strong evidence that androgen hormones play a role in the development of prostate 
cancer, as this cancer is not found in eunuchs and in people castrated before puberty. A series of 
environmental studies have also been conducted that have found a correlation between 
testosterone, especially dihydrotestosterone, in African Americans, Japanese and whites. 
Although many studies based on serum testosterone concentrations have not been consistent, 
some have shown an association between dihydrotestosterone, an active metabolite of 
testosterone, and the incidence of cancer. 
Some studies have found that obese people have a higher risk of more advanced and severe 
prostate cancer. Excessive alcohol consumption can be expected to affect hormone metabolism. 
Also cigarette smoking could play a biological role in carcinogenesis by ingesting certain 
carcinogenic metabolites present in smoke or by acting on hormones. Elevated cholesterol levels 
above 5.1 mmol / L are associated with an increased risk of prostate cancer because androgens in 
the human body are synthesized from cholesterol. Examination of wood-derived dust has led to 
striking conclusions that prostate cancer is common in woodworkers or exposed to wood dust. 
Also employed are people employed in thermal power plants, fire stations and railway stations 
due to exposure to polycyclic aromatic hydrocarbons. 
Symptoms are usually associated with urinary obstruction such as difficulty urinating, thin urine 
stream, urgency and frequent urination followed by hematospermia or blood in the semen, 
hypospermia due to blockage of the ejaculatory ducts and if metastatic it is most often in the 
bones causing pain, weight loss, anemia and paraplegia. [1-10] 
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Material and methods 
Statistical analysis of data for patients with prostate cancer in the period from 2014 to 2019was 
used as a method. The data are taken from Center for Public Health – Prilep. The data are 
presented in tabular and graphical presentation. 
 
Result and discussion 
The total number of registered patients was 228, of which 5 patients were diagnosed at the age of 
45-54 years, 40 patients were diagnosed at the age of 55-64 years, 103 patients were diagnosed at 
the age of 65-74 years and 80 patients were diagnosed with over 75 years of age. 
Table 1. Display of distribution of prostate cancer in accordance with the age diagnosed in 
patients on the territory of municipality of Prilep in the period from 2014 to 2019 
 
Year 45-54 55-64 65-74 75+ Total  
2014 2 5 29 18 54 
2015 2 7 16 15 40 
2016 1 8 18 13 40 
2017  5 10 12 27 
2018  6 15 16 37 
2019  9 15 6 30 
Total  5 40 103 80 228 
% 2.2% 17.5% 45.1% 35.2% 100% 
Based on the data obtained for prostate cancer from the Center for Public Health - Prilep, shown 
in table 1 for the period of 5 years 2014-2019, it can be noted that the total number of patients is 
228 people. The highest number of patients is in 2014, 54 patients, and the lowest in 2017, 27 
patients. 
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Chart 1.Graphic display of total number of diagnosed patients in accordance with the age when 
the prostate cancer was diagnosed on the territory of municipality of Prilep in the time period 
from 01.01.2014 to 31.12.2019 
 
 
Chart 2.Graphic display of total number of diagnosed patients according to the age and the year 









Chart3. Percentage graph of age when the prostate cancer appeared on the territory of 
municipality of Prilep in the time period 2014-2019 
From the graphic presentation in chart 1, it can be seen that the total number of diagnosed 
patients with prostate cancer in the period 2014-2019 in the municipality of Prilep is 228, 
according to the year of diagnosis in 2014, 54 patients, in 2015 and 2016 40 patients each, in 
2017, 27 patients, in 2018, 37 and in 2019, 30 patients. Thus, it can be noticed that the largest 
number of diagnosed patients is in 2014, then the number in 2015, 2016 and 2017 decreases, so 
in 2018 there is a slight increase in the number of newly diagnosed patients, while in 2019 we 
record a decrease in the number of newly diagnosed prostate cancer patients. 
                       International Journal of Medical Science and Health Research 
Vol. 5, No. 04; 2021 
ISSN: 2581-3366 
www.ijmshr.com Page 48 
 
From the graphic representation of chart 2, it can be seen that prostate cancer in the period 2014-
2019 in patients aged 45-54 is the least represented by only 5 patients, two in 2014 and 2015 and 
only one diagnosed patient in 2016, while in the remaining years of interest in this study there 
are no patients diagnosed with prostate cancer at this age or a percentage of only 2.2% which can 
be seen in chart 3 
From 55-64 years, 40 patients were diagnosed, 5 in 2014 and 2017, 7 in 2015, 8 in 2016, 6 in 
2018 and 9 patients in 2019 or a percentage of 17.5% shown in Figure 3 From 65-74, a total of 
103 patients were diagnosed or 45.1% shown in Figure 3, which can be concluded that most of 
the patients diagnosed with prostate cancer belong to this age group. According to the year of 
diagnosis, the distribution of prostate cancer at this age is: 29 in 2014, 16 in 2015, 18 in 2016, 10 
in 2017 and 15 in 2018 and 2019. In persons over 75 years of age in the period 2014-2019, 80 
patients were diagnosed with prostate cancer or 35.2% (Chart3) or the second most common age 
group after that between 65-74 years of age. According to the year of diagnosis, the distribution 
is: 18 in 2014, 15 in 2015, 13 in 2016, 12 in 2017, 16 in 2018 and 6 patients in 2019. 
Prostate cancer is the second most common cancer in the male population, and the fifth leading 
cause of death in men worldwide. Prostate cancer can be asymptomatic or often have an 
inconsistent growth pattern, so active monitoring is needed. The incidence and prevalence of 
prostate cancer are closely related to the age of patients, especially in people over 65 years of 
age. The incidence in African Americans is higher than in the other ethnical groups, due to 
changes in gene alleles and lifestyle itself. To reduce the risk, it is necessary to eliminate 
excessive consumption of fast food and replace it with a large amount of fruits and vegetables. 
Prostate cancer is the second most common cancer in the male population in the world, after lung 
cancer. It is a global health problem, due to the high incidence and large number of newly 
diagnosed and deceased patients globally. In 2018, about 358 000 patients died as a result of 
prostate cancer, which is 3.8% of all causes of death in the male population, while in 2020 the 
mortality was the same 3.8%, but in 2020 about 375 thousand died patients diagnosed with 
prostate cancer. Differences in the numbers of newly diagnosed prostate cancer patients between 
different countries are still not well understood, as the reason is the screening and different views 
of the annual urological examination supplemented by PSA and PAP examinations of patients. 
According to these differences, the differences can be seen in the numbers of prostate cancer 
patients on different continents. For example, in 2018, 450 000 new cases of prostate cancer 
were diagnosed in Europe, which represented 24% of all cancers that year. While in the United 
States are registered about 160 thousand or 9.8%. [1-10] 
Conclusion 
In men over the age of 65, the incidence of cancer increases by 60%. Mortality per year due to 
prostate cancer is about 10.7 per 100 thousand inhabitants. According to these parameters stated 
for the possibility of occurrence and mortality of patients, every man over the age of 50 should 
have a prostate examination once a year. Above all, a detailed urological examination is 
required, ie digital rectal examination, trans-rectal ultrasonography supplemented with laboratory 
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examination, ie examination of prostate specific antigen (PSA) and prostatic alkaline 
phosphatase (PAP). Screening is of great importance in detecting early prostate cancers that are 
still controllable. Annual examination prevents the development of severe forms of cancer and 
on-time detection, so there might be a greater possibility for its timely treatment and for 
prolonging the life of patients. 
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